Author

C. Camacho-Toledano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

D. Clemente· 2 shared I. Machin-Diaz· 2 shared A. Gonzalez-Mayorga· 1 shared D. Otaegui· 1 shared F. J. Palomares· 1 shared J. Garcia-Arocha· 1 shared J. M. Garcia-Dominguez· 1 shared L. Calahorra· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. Clemente

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GRAPHENE OXIDE AS A NOVEL IMMUNOTHERAPY TOOL FOR THE MODULATION OF MYELOID-DERIVED SUPPRESSOR CELL ACTIVITY IN THE CONTEXT OF MULTIPLE SCLEROSIS

C. Camacho-Toledano, I. Machin-Diaz, R. Lebron-Galan, A. Gonzalez-Mayorga, F. J. Palomares, M. C. Serrano, D. Clemente

This paper shows that graphene oxide substrates with different redox states and roughness modulate the immunosuppressive activity of MDSCs in vitro, suggesting potential therapeutic applications for MS.

bioRxiv · Mar 28, 2023 · PreprintImmunology

Peripheral Myeloid-Derived Suppressor Cells are good biomarkers of the efficacy of Fingolimod in Multiple Sclerosis

C. Camacho-Toledano, I. Machin-Diaz, L. Calahorra, M. Cabanas, D. Otaegui, T. Castillo-Trivino, L. M. Villar, L. Costa-Frossard, M. Comabella, L. Midaglia, J. M. Garcia-Dominguez, J. Garcia-Arocha, M. C. Ortega, D. Clemente

This study shows that baseline levels of monocytic-MDSCs predict fingolimod efficacy in MS patients and EAE mice.

bioRxiv · Aug 22, 2022Immunology